TCiv

Shanghai Gynecologic Oncology Group · Phase 2 active Small molecule

TCiv, developed by the Shanghai Gynecologic Oncology Group, is an investigational intraperitoneal chemotherapy regimen for ovarian cancer. Despite no FDA approval, it has shown promise in Phase 2 and Phase 3 trials, demonstrating potential as a first-line treatment option.

At a glance

Generic name	TCiv
Also known as	taxane, platinum
Sponsor	Shanghai Gynecologic Oncology Group
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TCiv CI brief — competitive landscape report
TCiv updates RSS · CI watch RSS
Shanghai Gynecologic Oncology Group portfolio CI